JP2024502189A5 - - Google Patents

Info

Publication number
JP2024502189A5
JP2024502189A5 JP2023541750A JP2023541750A JP2024502189A5 JP 2024502189 A5 JP2024502189 A5 JP 2024502189A5 JP 2023541750 A JP2023541750 A JP 2023541750A JP 2023541750 A JP2023541750 A JP 2023541750A JP 2024502189 A5 JP2024502189 A5 JP 2024502189A5
Authority
JP
Japan
Prior art keywords
sequence
referred
here
harg
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502189A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2022/050055 external-priority patent/WO2022148979A1/en
Publication of JP2024502189A publication Critical patent/JP2024502189A/ja
Publication of JP2024502189A5 publication Critical patent/JP2024502189A5/ja
Pending legal-status Critical Current

Links

JP2023541750A 2021-01-11 2022-01-11 癌を処置する方法 Pending JP2024502189A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163135865P 2021-01-11 2021-01-11
US202163135858P 2021-01-11 2021-01-11
US63/135,858 2021-01-11
US63/135,865 2021-01-11
US202163138019P 2021-01-15 2021-01-15
US63/138,019 2021-01-15
PCT/GB2022/050055 WO2022148979A1 (en) 2021-01-11 2022-01-11 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2024502189A JP2024502189A (ja) 2024-01-17
JP2024502189A5 true JP2024502189A5 (cg-RX-API-DMAC7.html) 2025-01-21

Family

ID=80446048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541750A Pending JP2024502189A (ja) 2021-01-11 2022-01-11 癌を処置する方法

Country Status (9)

Country Link
US (1) US20250186539A2 (cg-RX-API-DMAC7.html)
EP (1) EP4274597A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502189A (cg-RX-API-DMAC7.html)
KR (1) KR20230146528A (cg-RX-API-DMAC7.html)
AU (1) AU2022206395A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204630A1 (cg-RX-API-DMAC7.html)
IL (1) IL304275A (cg-RX-API-DMAC7.html)
MX (1) MX2023008193A (cg-RX-API-DMAC7.html)
WO (1) WO2022148979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
EP4704904A1 (en) * 2023-05-04 2026-03-11 Tambo, Inc. Tetrazine-based targeting agents for in vivo delivery of a payload
WO2025125648A1 (en) * 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide complex for use in treating cancer
WO2025125652A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer
WO2025214417A1 (en) * 2024-04-10 2025-10-16 Syneron Technology Co. Ltd. Cyclic peptide compounds and compositions as egfr inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
MX2019007367A (es) 2016-12-23 2020-01-27 Bicycletx Ltd Ligandos de peptido para enlace a mt1-mmp.
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CA3095582A1 (en) * 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220275053A1 (en) * 2019-08-13 2022-09-01 Bicycletx Limited Modified multimeric bicyclic peptide ligands
SI4464721T1 (sl) * 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
WO2022038158A1 (en) * 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof

Similar Documents

Publication Publication Date Title
US20250186539A2 (en) Methods for treating cancer
ES2754557T3 (es) Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia
CN112533944A (zh) 多特异性结合蛋白及其改进
JP7296958B2 (ja) 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ
KR20160108310A (ko) 암 치료를 위한 항-ceacam1 및 항-pd 항체를 포함하는 조성물
CN114786701B (zh) 用于治疗癌症的包括包含il-2蛋白和cd80蛋白的融合蛋白和免疫检查点抑制剂的药物组合物
CA3161364A1 (en) Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
IL301454A (en) Clinical dosing of SIRP1A chimeric protein
WO2023086929A1 (en) Sirp1a - and cd40l-based chimeric proteins
EP3795588B1 (en) Hla-b57 open conformers
CN117561277A (zh) 治疗克隆性t细胞扩增的方法和材料
KR20230056761A (ko) Pd-1 저해제의 투여에 의한 암 치료 방법
WO2019204402A1 (en) Compositions and methods for treatment of cancer
RU2795594C2 (ru) Пептитело glp-2 для введения до, в течение или после хирургического вмешательства
WO2024173352A2 (en) Methods of treating cancer with a sirp1a-based chimeric protein
WO2025125652A1 (en) Combination therapy for use in treating cancer
EP3568142B1 (en) Therapeutic peptides that target tgf-beta interaction
HK40120666A (en) Methods for enhancing immune checkpoint inhibitor therapy
CN118510812A (zh) 基于sirp1a和cd40l的嵌合蛋白
BR112022010246B1 (pt) Uso de um dímero de proteína de fusão que compreende uma variante il-2 e um fragmento cd80 para prevenir ou tratar câncer
HK40005313A (en) Combination therapy for cancer